ARTICLE | Clinical News
Avanir starts Phase II/III trial
December 20, 2000 8:00 AM UTC
AVN began a U.S. Phase II/III trial of its AVP-923 compound, which combines the NMDA receptor antagonist dextromethorphan with an enzyme inhibitor that slows dextromethorphan metabolism, to treat emot...